academic article

• Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial..  Lancet neurology.  19:988-997. 2020
• Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study..  Lancet.  391:1263-1273. 2018
• Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis..  The New England journal of medicine.  376:221-234. 2017
• Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis..  The New England journal of medicine.  376:209-220. 2017
• Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial..  Lancet.  380:1819-1828. 2012
• Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010..  International journal of MS care.  14:105-114. 2012